DOWNSTAGING LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA (LAPC) WITH

VASCULAR ENCASEMENT USING PERCUTANEOUS IRREVERSIBLE ELECTROPORATION (IRE)

NARAYANAN,GOVINDARAJAN; ARORA,GEETIKA;BARBERY, KATUSKA;FROUD,TATIANA;LIVINGSTONE,ALAN;

FRANCESCHI,DIDO; HOSEIN,PETER;ROCHA LIMA,CAIO;YRIZARRY,JOSE

PANCREATIC CANCER

• 5-year survival rate of 6%

• Case-fatality rate among the highest of any malignancy

• Surgical resection offers the best chance for cure, but only 10%-20% of patients will qualify

• American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society 2011.• American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society 2011.• American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society 2011.• American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society 2011.• American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society 2011.

WHAT IS LOCALLY ADVANCED PANCREATIC CANCER (LAPC)?

Pancreatic cancer that has not spread to distant organs (Non-metastatic disease) but is inoperable due to encasement of major blood vessels.

CURRENT TREATMENT OPTIONS

• Surgery

• Chemotherapy

• Radiation therapy

WHAT IS IRREVERSIBLE ELECTROPORATION (IRE)?

A focal ablation therapy that uses high voltage low energy DC electrical pulses to permanently open pores in the cell membranes of soft tissue, which causes cells to die.

• Has a 510(k) clearance from the FDA for soft tissue ablation

• Use in organs is considered off-label

NANOKNIFE GENERATOR

THERMAL ABLATION OPTIONS

• RADIO FREQUENCY ABLATION

• MICROWAVE ABLATION

PURPOSE OF THE STUDY

• Safety of IRE in treating Pancreatic Cancer without open surgery with imaging guidance

• Resection rate in LAPC after using IRE

TREATMENT CRITERIA

• Patients who failed previous chemotherapy and radiation treatment

• Patients with unresectable pancreatic tumors

• Patients with minimal and stable metastatic disease

RECENT ANALYSIS

• 8 patients treated between 12/2010 – 9/2011

• Most patients had received prior chemotherapy and or radiation

• Median time between diagnosis and IRE: 9 months

• 2 went to surgery. Both had successful resections and remain cancer-free. ( 346 and 225 days post surgery)

WHY THIS MATTERS TO PATIENTS?

• A new option, with potential ability to down stage

• Minimal side effects and morbidity

• Other treatment options can still be used

PANCREAS IRE CASE

• 65yr old female• Biopsy proven pancreatic cancer• Received Chemotherapy and radiation• Inoperable due to vessel encasement and residual

disease

PRE IRE CT

Tumor after chemotherapy and radiation therapy

Celiac axis and SMA encasement

11/10- ELECTRODE PLACEMENT UNDER CAT SCAN GUIDANCE

IRE probe placement

IMMEDIATE POST CT SCAN

Unaffected vessels and air surrounding the treatment zone

FOLLOW UP CT 3/11

Vessel encasement

SURGERY 4/11

• Tumor involved body & neck

• Distal Pancreatectomy & Splenectomy

• Proximal pancreatic margin frozen sample- Negative

PATHOLOGY

Extensive fibrosis Residual Intraductal Mucinous Ca

FOLLOW UP

Follow up days: 421 CT :1/24/2012: No enhancing mass- No evidence of

Disease Disease status: Stable CA-19-9: Decreasing trend from 24.2 to 15.8

What we know & Where we go from here

• Can be done safely with imaging guidance.

• Early results in a small number of patients is promising

• Trial to validate these results

Thank You